[177Lu]Lu-PNT2002 consists of a beta-emitting [177Lu]lutetium radioisotope chelated to a small-molecule ligand (also known as PSMA-Imaging & Therapy [I&T]) that targets PSMA using a glutamate urea-based pharmacophore, enabling targeted delivery of radiation to prostate cancer cells, causing DNA damage and ultimately cancer cell death. This evidence concerns the gene FOLH1 and prostate cancer.